Lombard Medical, which develops stent-grafts for endovascular aorta repair, filed on Monday with the SEC to raise up to $80 million in an initial public offering. The company currently trades on the LSE AIM under the ticker LMT but intends to delist in conjunction with its US offering. The Oxfordshire, United Kingdom-based company, which was founded in 2003 and booked $7 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol EVAR. Lombard Medical initially filed confidentially on January 22, 2014. Jefferies and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
